AlzeCure Pharma (ALZCUR) Status Update summary

Orphan Drug Market Overview

• Orphan drugs target rare diseases, defined as affecting fewer than 200,000 people in the U.S. or fewer than 5 in 10,000 in the EU, with ultra-orphan diseases affecting even smaller populations.

• The global orphan drug market reached $195.2 billion in 2024 and is projected to exceed $300 billion by 2030, growing at 10–12% annually, double the rate of the broader pharma sector.

• Orphan drugs benefit from incentives like faster development, long market exclusivity (7 years U.S., 10 years EU), reduced development costs, tax credits, and expedited regulatory pathways.

• Premium pricing and high unmet medical need drive strong commercial interest from both big pharma and investors, with orphan drugs often priced 17 times higher than common drugs.

• Orphan drug development has pioneered precision medicine, with targeted therapies and advanced diagnostics now influencing broader healthcare.

Erythromelalgia and Unmet Need

• Erythromelalgia is a rare, chronic, and disabling pain disorder with no approved medical treatments, characterized by intense, heat-triggered pain flares.

• Prevalence is estimated at 43,000–70,000 individuals in the U.S. (about 13 per 100,000), qualifying for orphan status and causing significant socioeconomic impact.

• Current management relies on cooling, which can cause complications; there are no approved or effective drugs for this indication.

• Over 90% of rare diseases still lack treatments, highlighting the substantial unmet medical need.

ACD 440 and Clinical Opportunity

• ACD 440 is a topical TRPV1 antagonist gel developed for pain in erythromelalgia and is in clinical Phase II for neuropathic pain.

• ACD 440 has shown a 50% reduction in heat-induced pain in both healthy subjects and patients with chronic neuropathic pain in clinical studies.

• Orphan drug designation for ACD 440 in erythromelalgia brings regulatory, financial, and market exclusivity advantages, with positive FDA feedback on the development program.

• ACD 440 is expected to be a lifelong treatment for erythromelalgia, with no evidence of desensitization or tolerance development.